Form 4: Kestra Medical CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Kestra Medical Technologies CEO Brian Daniel Webster sold 15,000 common shares for a weighted average price of $22.8016, executed under a pre-arranged 10b5-1 trading plan.
Summary
- Brian Daniel Webster, President and CEO of Kestra Medical Technologies, Ltd. (KMTS), reported a sale of common shares.
- The transaction involved the disposition of 15,000 common shares.
- The shares were sold at a weighted average price of $22.8016 per share, with prices ranging from $22.2800 to $23.1340.
- The sale occurred on January 15, 2026.
- Following this transaction, Mr. Webster beneficially owns 394,786 common shares directly.
- The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
Sentiment
Score: 5
Explanation: The transaction is a pre-planned insider sale under a 10b5-1 plan, which is generally considered neutral as it is not indicative of new information or a reaction to recent events.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent events, which can reduce concerns about opportunistic insider selling.
Negatives
- An insider sale, even if planned, reduces the direct ownership stake of a key executive, which some investors might interpret as a slight reduction in alignment of interests.
Future Outlook
NA
Industry Context
This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reported transaction was made pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025, which allows insiders to set up a pre-arranged plan to buy or sell company stock. | 09/29/2025 | A 10b5-1 plan helps mitigate concerns about insider trading by demonstrating that the transaction was planned when the insider was not in possession of material non-public information. |
Stakeholder Impact
- Shareholders: A minor reduction in direct insider ownership, but the pre-planned nature under Rule 10b5-1 typically minimizes negative interpretations.
Key Dates
| Date | Description |
|---|---|
| 09/29/2025 | Date Rule 10b5-1 trading plan was adopted. |
| 01/15/2026 | Date of common shares transaction. |
| 01/20/2026 | Date Form 4 was signed. |
Keywords
Kestra Medical Technologies, KMTS, Brian Daniel Webster, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.